Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.78 |
| ▸ | POLB | P06746 | 8/20 | 0.78 |
| ▸ | TNF | P01375 | 2/20 | 0.78 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.78 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.78 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.78 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.78 |
| ▸ | CXCR2 | P25025 | 3/20 | 0.73 |
| ▸ | ACMSD | Q8TDX5 | 4/20 | 0.71 |
| ▸ | BRD4 | O60885 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23892607 | 0.89 | ACMSD (0.79) | MEN1KMT2APOLBTNFNOD2 | |
| SCHEMBL20468620 | 0.86 | MEN1 (0.89) | MEN1KMT2APOLBTNFNOD2 | |
| SCHEMBL20099429 | 0.86 | ACMSD (0.95) | MEN1KMT2APOLBTNFNOD2 | |
| SCHEMBL16772524 | 0.85 | ACMSD (0.84) | MEN1KMT2APOLBTNFNOD2 | |
| SCHEMBL16775370 | 0.84 | ACMSD (0.91) | MEN1KMT2APOLBTNFNOD2 | |
| SCHEMBL23892718 | 0.83 | ACMSD (0.75) | MEN1KMT2APOLBTNFNOD2 | |
| SCHEMBL20099425 | 0.82 | ACMSD (0.76) | MEN1KMT2APOLBTNFNOD2 | |
| SCHEMBL29554641 | 0.82 | BRD4 (1.00) | MEN1KMT2APOLBTNFNOD2 | |
| SCHEMBL29272646 | 0.82 | BRD4 (1.00) | MEN1KMT2APOLBTNFNOD2 | |
| SCHEMBL5937460 | 0.82 | MEN1 (0.66) | MEN1KMT2APOLBTNFNOD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180222880-A1 | SecA INHIBITORS AND METHODS OF MAKING AND USING THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-08-09 | — | — | US | disclosed |
| US-9957247-B2 | SecA inhibitors and methods of making and using thereof | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2018-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222880-A1 | SecA INHIBITORS AND METHODS OF MAKING AND USING THEREOF | SEC61B, SEC61A1, SEC23A | MEN1 2848/4885KMT2A 4137/4885POLB 2638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.